Mass spectrometry in clinical laboratory: applications and future prospects
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20233951Keywords:
Mass, Spectrometry, Diagnosis, Laboratory, TherapeuticAbstract
Innovations in laboratory medicine face additional challenges due to the unmet need for extremely precise methods of disease diagnosis. Developments in mass spectrometry-based disease biomarker identification are constantly expanding the field of clinical diagnosis. More mass spectrometry-based in vitro diagnostics are anticipated to move from the bench to the bedside shortly, although several are currently incorporated into standard clinical procedures. The molecular detection by mass spectrometry technique is very effective in diagnosis of the disease and therapeutic monitoring because of its extremely high sensitivity, specificity, and short turnaround time. Mass spectrometry is a potent analytical instrument that may be used to analyse a variety of materials and matrices; its use in clinical laboratory medicine applications is rising. For clinical prognostics and diagnostic purposes, mass spectrometry imaging has been widely utilized to distinguish between healthy and diseased tissues. Modern single-cell studies will benefit from its cutting-edge applications, which will offer comprehensive cellular biochemical data for mechanistic comprehension and, eventually, the development of therapeutic interventions. Within the field of laboratory medicine, the application of mass spectrometry is crucial, especially in terms of diagnostics and therapeutic drug monitoring. This review on the clinical application of mass spectrometry and its future prospects promises an insightful exploration of the evolving landscape of mass spectrometry in clinical settings, delving into its current applications and shedding light on its potential future advancements, for which a comprehensive search in the PubMed, ScienceDirect, and Web of Science databases was conducted.
References
Xu QA, Madden TL. LC-MS in drug bioanalysis: Springer Science & Business Media. 2012.
Király M, Dalmadiné Kiss B, Vékey K, Antal I, Ludányi K. [Mass spectrometry: past and present]. Acta Pharmaceutica Hungarica. 2016;86(1):3-11.
Matthiesen R, Bunkenborg J. Introduction to mass spectrometry-based proteomics. Methods in molecular biology (Clifton, NJ). 2013;1007:1-45.
Banerjee S. Empowering Clinical Diagnostics with Mass Spectrometry. ACS Omega. 2020;5(5):2041-8.
Jannetto PJ, Fitzgerald RL. Effective Use of Mass Spectrometry in the Clinical Laboratory. Clin Chem. 2016;62(1):92-8.
Puglisi R, Boeri Erba E, Pastore A. A Guide to Native Mass Spectrometry to determine complex interactomes of molecular machines. FEBS J. 2020;287(12):2428-39.
Colby JM, Thoren KL. Chapter 21 - Applications of mass spectrometry in the clinical laboratory. In: Clarke W, Marzinke MA, editors. Contemporary Practice in Clinical Chemistry (Fourth Edition): Academic Press. 2020;351-63.
Moore JL, Patterson NH, Norris JL, Caprioli RM. Prospective on Imaging Mass Spectrometry in Clinical Diagnostics. Molecular & cellular proteomics: MCP. 2023;22(9):100576.
Croxatto A, Prod'hom G, Greub G. Applications of MALDI-TOF mass spectrometry in clinical diagnostic microbiology. FEMS Microbiol Rev. 2012;36(2):380-407.
Sarvestani HK, Ramandi A, Getso MI, Razavyoon T, Javidnia J, Golrizi MB, et al. Mass spectrometry in research laboratories and clinical diagnostic: a new era in medical mycology. Braz J Microbiol. 2022;53(2):689-707.
Ye H, Gemperline E, Li L. A vision for better health: mass spectrometry imaging for clinical diagnostics. Clin Chim Acta. 2013;420:11-22.
Lazova R, Seeley EH, Keenan M, Gueorguieva R, Caprioli RM. Imaging mass spectrometry--a new and promising method to differentiate Spitz nevi from Spitzoid malignant melanomas. Am J Dermatopathol. 2012;34(1):82-90.
Crutchfield CA, Thomas SN, Sokoll LJ, Chan DW. Advances in mass spectrometry-based clinical biomarker discovery. Clin Proteomics. 2016;13:1.
Crutchfield CA, Thomas SN, Sokoll LJ, Chan DW. Advances in mass spectrometry-based clinical biomarker discovery. Clinical Proteomics. 2016;13(1):1.
Swiner DJ, Jackson S, Burris BJ, Badu-Tawiah AK. Applications of Mass Spectrometry for Clinical Diagnostics: The Influence of Turnaround Time. Analytical Chem. 2020;92(1):183-202.
Miller WL, Phelps MA, Wood CM, Schellenberger U, Van Le A, Perichon R, et al. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail. 2011;4(3):355-60.
Suzuki T, Israr MZ, Heaney LM, Takaoka M, Squire IB, Ng LL. Prognostic Role of Molecular Forms of B-Type Natriuretic Peptide in Acute Heart Failure. Clin Chem. 2017;63(4):880-6.
Heaney LM, Jones DJ, Suzuki T. Mass spectrometry in medicine: a technology for the future? Future Sci OA. 2017;3(3):Fso213.
Avataneo V, D'Avolio A, Cusato J, Cantù M, De Nicolò A. LC-MS application for therapeutic drug monitoring in alternative matrices. J Pharm Biomed Analysis. 2019;166:40-51.
Kuhlin J, Sturkenboom MGG, Ghimire S, Margineanu I, van den Elsen SHJ, Simbar N, et al. Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs. Clin Mass Spectrometry (Del Mar, Calif). 2019;14 Pt A:34-45.
Maurer HH. Mass Spectrometry for Research and Application in Therapeutic Drug Monitoring or Clinical and Forensic Toxicology. Ther Drug Monit. 2018;40(4):389-93.
Gaspar VP, Ibrahim S, Zahedi RP, Borchers CH. Utility, promise, and limitations of liquid chromatography-mass spectrometry-based therapeutic drug monitoring in precision medicine. J Mass Spectrometry. 2021;56(11):e4788.
Dias E, Hachey B, McNaughton C, Nian H, Yu C, Straka B, et al. An LC-MS assay for the screening of cardiovascular medications in human samples. J Chromatography Analytical Technol Biomed Life Sci. 2013;937:44-53.
Gao S, Wang Z, Xie X, You C, Yang Y, Xi Y, et al. Rapid and sensitive method for simultaneous determination of first-line anti-tuberculosis drugs in human plasma by HPLC-MS/MS: Application to therapeutic drug monitoring. Tuberculosis (Edinburgh, Scotland). 2018;109:28-34.
Decosterd LA, Mercier T, Ternon B, Cruchon S, Guignard N, Lahrichi S, et al. Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections. J Chromatography Analytical Technol Biomed Life Sci. 2020;1157:122160.
Barco S, Mesini A, Barbagallo L, Maffia A, Tripodi G, Pea F, et al. A liquid chromatography-tandem mass spectrometry platform for the routine therapeutic drug monitoring of 14 antibiotics: Application to critically ill pediatric patients. J Pharm Biomed Analysis. 2020;186:113273.
van der Gugten JG, Bressler B, DeMarco ML. An automated mass spectrometric blood test for therapeutic drug monitoring of infliximab. Clin Mass Spectrometry (Del Mar, Calif). 2019;12:16-22.
Cafaro A, Baiardi G, Pigliasco F, Barco S, Mattioli F, Volpi S, et al. A Novel LC-MS/MS Method for Therapeutic Drug Monitoring of Baricitinib in Plasma of Pediatric Patients. Ther Drug Monit. 2023;25.
Adaway JE, Keevil BG. Therapeutic drug monitoring and LC-MS/MS. J Chromatography Analytical Technol Biomed Life Sci. 2012;883-884:33-49.
Cui J-J, Wang L-Y, Tan Z-R, Zhou H-H, Zhan X, Yin J-Y. Mass spectrometry-based personalized drug therapy. Mass Spectrometry Rev. 2020;39(5-6):523-52.
Castillo J, Bernard V, San Lucas FA, Allenson K, Capello M, Kim DU, et al. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. Ann Oncol. 2018;29(1):223-9.
Kreimer S, Ivanov AR. Rapid Isolation of Extracellular Vesicles from Blood Plasma with Size-Exclusion Chromatography Followed by Mass Spectrometry-Based Proteomic Profiling. Methods Mol Biol (Clifton, NJ). 2017;1660:295-302.
Kogler S, Kømurcu KS, Olsen C, Shoji J-y, Skottvoll FS, Krauss S, et al. Organoids, organ-on-a-chip, separation science and mass spectrometry: An update. TrAC Trends in Analytical Chem. 2023;161:116996.
Zhu N, Xing X, Cao L, Zhang Y, Zhang T, Li Z, et al. Study on the Diagnosis of Gastric Cancer by Magnetic Beads Extraction and Mass Spectrometry. BioMed Res Int. 2020;2743060.
Huang G, Zhang F, Xie D, Ma Y, Wang P, Cao G, et al. High-throughput profiling of RNA modifications by ultra-performance liquid chromatography coupled to complementary mass spectrometry: Methods, quality control, and applications. Talanta. 2023;263:124697.
Thomas SN, French D, Jannetto PJ, Rappold BA, Clarke WA. Liquid chromatography–tandem mass spectrometry for clinical diagnostics. Nat Rev Methods Primers. 2022;2(1):96.
